Education & Academic Qualifications
- 2009: Degree in Medicine, University of Patras, Medical School
- 2013: Master of Science (MSc), National School of Public Health
- 2014: PhD, University of Patras, Medical School
- 2018: Specialty Certificate in Nephrology
Master of Science (MSc)
National School of Public Health
TITLE: Comparison of Sense of Coherence index and Quality of life via SF-12 between patients on hemodialysis, patients with myocardial infarction and patients with arterial hypertension
University of Patras, School of Medicine, Greece
TITLE: Antiplatelet effects of prasugrel versus double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity
6/2019: Consultant, Centre for Diagnosis, Treatment & Research on Kidney Diseases
2018-2019: Clinical fellow, ERA-EDTA Young Fellowship Programme, in collaboration with the Hellenic Society of Nephrology and the Stavros Niarchos Foundation, King’s College London, Guy’s and St Thomas’ Foundation NHS Trust, Department of Diabetes & Endocrine, London, United Kingdom
2014-2018: Specialty Registrar in Nephrology, Centre for Nephrology “G. Papadakis”, General Hospital of Nikaia-Pireaus
2012-2014: Resident Doctor in Internal Medicine, 2nd Department of Internal Medicine, General Hospital of Nikaia- Pireaus
2010-2011: Community Doctor, General Hospital of Mesolongi “Chatzikosta”- Health Center of Ano Hora, Nafpaktos, Greece
2009-2010: Research Fellow, Cardiology Department, University Hospital of Patras
My clinical experience lies in all the fields of Nephrology (Clinical Nephrology, Hemodialysis, Peritoneal Dialysis) and this is because the Nephrology Centers I was trained and educated are the most experienced in their countries. My main interest is Diabetic Nephropathy and cardiovascular complications of Diabetes Mellitus as I was trained and subspecialized in Metabolic Unit of King’s College London.
Clinical and Research Interests
Clinical Nephrology and mainly Diabetic Nephropathy
Renal Replacement Therapy (Haemodialysis)
Lysosomal diseases (Fabry disease)
The clinical and epidemiological research in Diabetic Nephropathy emphasizing in newer therapies of Diabetes Mellitus and risk factors for renal and cardiovascular complications of diabetes with the development of prognostic models of progression.
Fabry patients in Greece
5th Fabry Expert Meeting, Athens, 2017
Fabry disease: From laboratory to everyday clinical practice
Scientific meeting for Lysosomal Diseases, Athens, 2016
IgA Nephropathy: Case report Centre for Nephrology
19th Panhellenic Congress of Nephrology, Kalamatas, 2016
Member of Scientific Societies
Hellenic Society of Nephrology
European Renal Association-European Dialysis Transplant Association
European Association for the Study of Diabetes (EASD)
European Diabetic Nephropathy Study Group (EDNSG)
Member of General Medical Council (GMC)
Clinical Fellowship. ERA-EDTA Young Clinical Fellowships for Greek Nephrologists Programme 2018
10/2018 – 6/2019: Guy’s and St Thomas’ NHS Foundation Trust, Diabetes & Endocrine Department, London, United Kingdom
IgA nephropathy in Greece: Data from the registry of the Hellenic Society of Nephrology
Stangou, M. Papasotiriou, D. Xydakis, T. Oikonomaki, S. Marinaki, S. Zerbala, C. Stylianou, P. Kalliakmani, A. Aimilios, A. Papadaki, O. Balafa, S. Golfinopoulos, G. Visvardis, G. Moustakas, E. Papachristou, T. Kouloukourgiotou, E. Kapsia, A. Panagiotou, C. Koulousios, C. Kavlakoudis, M. Georgopoulou, S. Panagoutsos, D. Vlahakos, T. Apostolou, I. Stefanidis, C. Siamopoulos, I. Tzanakis, A. Papadogiannakis, E. Daphnis, C. Iatrou, I. Boletis, A. Papagianni, D. Goumenos
Clin Kidney J. 2018 Feb; 11(1):38-45. doi: 10.1093/ckj/sfx076
Oral Antiplatelet Agents in Dialysis Patients: Friends or Foes?
Fourtounas C, Panagiotou A.
Gen Med (Los Angel) 2013, 1:3, http://dx.doi.org/10.4172/2327-5146.1000109
Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis.
Alexopoulos D, Xanthopoulou I, Panagiotou A, Komninakis D, Germanos N, Goudas P, Koutroulia E, Fourtounas C.
Am J Kidney Dis. 2012 Mar;59(3):469-71. doi: 10.1053/j.ajkd.2011.10.045.
Oral antiplatelet agents and chronic kidney disease
Alexopoulos D, Panagiotou A.
Hellenic J Cardiol. 2011 Nov-Dec;52(6):509-15.
Long-term clinical outcome after percutaneous coronary intervention in grafts vs native vessels in patients with previous coronary artery bypass grafting
Xanthopoulou I, Davlouros P, Tsigkas G, Panagiotou A, Hahalis G, Alexopoulos D.
Can J Cardiol. 2011 Nov-Dec;27(6):716-24. doi: 10.1016/j.cjca.2011.08.115.
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.
Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos D.
J Thromb Haemost. 2011 Dec;9(12):2379-85. doi: 10.1111/j.1538-7836.2011.04531.x.
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G.
Am Heart J. 2011 Oct;162(4):733-9. doi: 10.1016/j.ahj.2011.07.026.
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population.
Alexopoulos D, Xanthopoulou I, Mylona P, Perperis A, Panagiotou A, Dimitropoulos G, Tsigkas G, Hahalis G, Davlouros P.
J Thromb Thrombolysis. 2011 Oct;32(3):328-33. doi: 10.1007/s11239-011-0610-